Andere talen Bristol-Myers Squibb Company Wiener Boerse

Aandelen

BMYS

US1101221083

slotkoers Wiener Boerse Andere beurzen 00:00:00 14-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
38,95 ^EUR	+1,50%		+1,50%	-15,97%

13/06	Augtyro van Bristol-Myers Squibb krijgt versnelde goedkeuring van FDA voor behandeling van vaste tumoren	MT
12/06	Evotec ontvangt $20 miljoen voor samenwerking met Bristol Myers Squibb op het gebied van neurowetenschappen	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Bristol Myers : approbation de la FDA pour un traitement	14/06
Bristol-Myers Squibb's Augtyro Gets FDA Accelerated Approval for Treatment of Solid Tumors	13/06
Bristol Myers Squibb's Augtyro Gets FDA Accelerated Approval	13/06
U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors	13/06
Evotec to Receive $20 Million Under Neuroscience Partnership with Bristol Myers Squibb	12/06
Evotec Gets $20 Million Milestone Payment in Neurodegenerative Disease Collaboration With Bristol Myers Squibb	12/06
Evotec Announces Progress in Neuroscience Collaboration with Bristol Myers Squibb	12/06
Evotec erhält Forschungszahlung von 20 Mio USD von Myers Squibb	12/06
ABL Bio, BMS Collaborate on Gastric Cancer Treatment Trial	10/06
Geron shares surge after U.S. FDA approves blood disorder drug	07/06
I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers	05/06
Bristol Myers Squibb Announces Opdivo Plus Yervoy Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma	05/06
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers	05/06
Bristol-Myers Squibb Says Opdivo Plus Yervoy Therapy Improves Survival of Liver Cancer Patients	04/06
Bristol Myers : résultats positifs dans le cancer du foie	04/06
Bristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma in CheckMate -9DW Trial	04/06
Bristol Myers Squibb Announces Opdivo Plus Yervoy Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carinoma in Checkmate -9DW Trial	04/06
Bristol Myers Squibb to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference	04/06
Envisagenics, Inc. announced that it has received $25 million in funding from New York City Economic Development Corporation, Third Kind Venture Capital, Red Cell Management, LLC, Bristol-Myers Squibb Company	04/06
Bristol-Myers Squibb Says Breyanzi Studies Show 'Meaningful' Outcomes Across B-cell Malignancies	03/06

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Headlines

Bristol-Myers CEO zegt dat het bedrijf in overgang is

09 januari 2024 om 19:06 uur